Correlation Between Europlasma and Neovacs SA

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Europlasma and Neovacs SA at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Europlasma and Neovacs SA into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Europlasma SA and Neovacs SA, you can compare the effects of market volatilities on Europlasma and Neovacs SA and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Europlasma with a short position of Neovacs SA. Check out your portfolio center. Please also check ongoing floating volatility patterns of Europlasma and Neovacs SA.

Diversification Opportunities for Europlasma and Neovacs SA

0.76
  Correlation Coefficient

Poor diversification

The 3 months correlation between Europlasma and Neovacs is 0.76. Overlapping area represents the amount of risk that can be diversified away by holding Europlasma SA and Neovacs SA in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Neovacs SA and Europlasma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Europlasma SA are associated (or correlated) with Neovacs SA. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Neovacs SA has no effect on the direction of Europlasma i.e., Europlasma and Neovacs SA go up and down completely randomly.

Pair Corralation between Europlasma and Neovacs SA

Assuming the 90 days trading horizon Europlasma SA is expected to generate 0.62 times more return on investment than Neovacs SA. However, Europlasma SA is 1.62 times less risky than Neovacs SA. It trades about -0.62 of its potential returns per unit of risk. Neovacs SA is currently generating about -0.62 per unit of risk. If you would invest  3.46  in Europlasma SA on November 4, 2024 and sell it today you would lose (1.93) from holding Europlasma SA or give up 55.78% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Europlasma SA  vs.  Neovacs SA

 Performance 
       Timeline  
Europlasma SA 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Europlasma SA has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in March 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.
Neovacs SA 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Neovacs SA has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in March 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Europlasma and Neovacs SA Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Europlasma and Neovacs SA

The main advantage of trading using opposite Europlasma and Neovacs SA positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Europlasma position performs unexpectedly, Neovacs SA can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neovacs SA will offset losses from the drop in Neovacs SA's long position.
The idea behind Europlasma SA and Neovacs SA pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Other Complementary Tools

Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities